key: cord-0719356-p2qv08kc authors: Sandoval, Micaela; Hair, Adam W; Sharma, Shreela V; Troisi, Catherine L title: Characterizing COVID-19 case detection utilizing influenza surveillance data in the United States, January-March, 2020 date: 2020-04-29 journal: nan DOI: 10.1101/2020.04.23.20077651 sha: acef348c6c1ddae2fc7e71ba670631d4a555a01b doc_id: 719356 cord_uid: p2qv08kc COVID-19 reached the US in January, 2020, but state and local case detection efforts varied in timing and scale. We conducted a state-level ecological analysis of COVID-19 epidemiology alongside CDC influenza surveillance data and policy timelines. Our findings show wide variation in COVID-19 case detection and influenza-like-illness activity between states. surveillance data were used for this analysis as they are more representative of symptomatic patients presenting for care. Pneumonia and influenza mortality data is collected from state vital statistics offices by the National Center for Health Statistics using ICD-10 multiple cause of death codes [13] . This analysis included raw pneumonia death counts to reduce bias resulting from the inclusion of confirmed influenza deaths. Comparisons between geographic areas utilizing unweighted surveillance data is not appropriate, so this investigation focuses on characterizing each state's population individually. CDC influenza surveillance data was deemed unreliable by investigators after MMWR week 12 (March 22, 2020), and at time of writing, FluView has been abbreviated for the remaining season [13] . Our analysis focused on four US states with high COVID-19 incidence. Cumulative incidence (January 22 to April 16, 2020) varied widely from 144 cases to 1,150 cases per 100,000 population, despite homogeneity in stay at home order dates (Table 1) . Of the selected states, only Washington exhibited a higher than average number of negative influenza tests resulted by clinical laboratories participating in the WHO or NREVSS systems in the first eight weeks of 2020 ( Figure 1 ). In Washington, New York, and Louisiana, week 12 increases in reported negative influenza tests were eclipsed by incident COVID-19 cases. However, in Colorado, negative influenza tests increased markedly from week 9 to week 12. Testing volume in MMWR weeks 10-12 varied widely between states ( Figure 2 ). Notably, in Colorado, testing volume was low in relation to negative influenza tests. With the exception of Washington, states did not document significant COVID-19 mortality until week 12 ( Table 2 ). Colorado and Washington demonstrated higher than average pneumonia deaths in week 12. While cumulative incidence was similar in Colorado and Washington (144 and 145 cases per 100,000 pop, respectively), testing rates in Colorado were less than half testing rates in Washington, and hospitalization rates in Colorado were 3.7 times hospitalization rates in Washington. Additionally, Washington and Colorado both reported negative influenza tests in excess of the 2016-2019 mean for weeks 11 and 12, but confirmed COVID-19 cases accounted for almost 80% of excess negative influenza tests in Washington and only 16% of excess tests in Colorado. In weeks 10 to 12, Washington implemented COVID-19 testing at 334 tests per 100,000 population, while Colorado conducted only 66 tests per 100,000 population. In contrast, neither New York nor Louisiana exhibited significant excess negative influenza tests or pneumonia mortality during MMWR weeks 1 to 12. While both states utilized high testing rates, New York's incidence and hospitalization rate were 2.4 and 2.7 times Louisiana's, respectively. At the time of writing this manuscript, the New York City metropolitan area bears the highest disease burden in the US, and NYC caseloads drive the epidemiologic characteristics of the country. Discussion. This ecological analysis was conducted on publicly available surveillance data amidst a rapidly evolving outbreak. Confounding from differential surveillance reporting, prevalence of risk factors, differences in social distancing guidance, and changes in health-seeking behavior is likely. The data presented is not representative of the United States and should not be extrapolated. Although we were not able to estimate influenza-like-illness burden or pneumonia mortality throughout the outbreak, the results of this hypothesis-generating analysis provide compelling evidence for further studies. The proportion of confirmed COVID-19 cases requiring hospitalization is impacted by both disease severity in the population and case detection rate. The extraordinarily high hospitalization rates and in All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 29, 2020. . Colorado and New York likely belie a large population of undetected cases. Case fatality rates may be influenced by health system capacity in addition to detection bias. While passive surveillance and COVID-19 testing data cannot be linked at an individual level due to the ecological nature of the study, sharp increases in negative influenza tests correspond to additional patients presenting with symptoms such as fever, cough, sore throat, and body aches for whom influenza is not present. Excess pneumonia mortality likewise suggests an increase in severe respiratory infections, presumably COVID-19. Colorado's epidemiologic profile in particular demonstrates a concerning discrepancy between influenza like illness disease burden and reported incidence of COVID-19. Our findings depict startling heterogeneity in COVID-19 surveillance as defined by testing across highincidence states. The volume of negative influenza tests and pneumonia mortality data likely underestimate true rates of influenza-like-illness and mortality, due to lags in reporting, changing health-seeking behaviors, test shortages, and rising telehealth modalities. Additionally, these proxies estimate symptomatic cases; evidence shows COVID-19 transmission is largely precipitated by asymptomatic or pre-clinical carriers [14] . Our findings indicate a vast deficit in COVID-19 detection which must be resolved before transmission can be effectively contained. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. COVID-19 data retrieved from Johns Hopkins University dashboard, April 16, 2020. Influenza surveillance data retrieved from CDC Influenza Surveillance dashboard, April 17, 2020. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia COVID-19 and Italy: what next? The Lancet Covid-19 -Navigating the Uncharted Defining the Epidemiology of Covid-19 -Studies Needed Presymptomatic Transmission of SARS-CoV-2 -Singapore Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts. The Lancet Global Health Evaluation of the Effectiveness of Surveillance and Containment Measures for the First 100 Patients with COVID-19 in Singapore An interactive web-based dashboard to track COVID-19 in real time Excess cases of influenza-like illnesses synchronous with coronavirus disease (COVID-19) epidemic, France National and State Population Estimates Boston University School of Public Health: Available at: www.tinyurl.com/statepolicies. 13. Overview of Influenza Surveillance in the United States Presumed Asymptomatic Carrier Transmission of COVID-19 COVID-19 case, death, test, and hospitalization data retrieved from Johns Hopkins University dashboard, April 16, 2020. Pneumonia mortality data retrieved from CDC Influenza Surveillance dashboard, April 17, 2020.